General Assembly — an international presence in digital education — announced an expansion to Houston. Getty Images

General Assembly — a global organization that offers programming for digital skill development — has announced its newest location in Houston.

"We're happy to announce that with our expansion into Houston, General Assembly now has a physical presence in the ten largest cities in the country," says Jake Schwartz, CEO and co-founder of General Assembly, in a news release. "Our launch today displays our commitment to expanding the accessibility of our educational programs to all Americans, and hopefully revolutionizing the future of work and education."

General Assembly will be located in the Ion Smart Cities Accelerator at 1301 Fannin St. The organization will launch a three-month software engineering program in January along with workshops and introductory courses before rolling out other part- and full-time courses in 2020.

"General Assembly's arrival in Houston will provide a huge boost to an already rapidly growing tech hub in the city directly, but also in the state of Texas overall," says Houston City Lead Gabriela Zahoranska in the release. "As the fourth biggest city in the country, the need for in-demand tech skills-training has grown expeditiously, and will help empower our community by giving them the tools they need to do the work they love."

The programming premieres today with a panel at Station. The new center's launch represents the 25th location for GA, and the company has new campuses planned for next year.

"In order to keep up with the rapidly changing technology landscape, today's workforce needs to be committed to life-long learning and upskilling," says Steven Rader, deputy director for the Center of Excellence for Collaborative Innovation at NASA, in the release. "Organizations need to start pivoting to the emerging open talent (gig/freelance) workforce and associated platforms as a way to find and access the skills and technologies they need to stay competitive."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”